HR1405-01

1) To observe the tolerance of Chinese healthy subjects to multiple intravenous administration of HR1405-01 injection, preliminarily evaluate the human safety of HR1405-01 injection, and provide a safe dose range for later clinical trials. 2) To evaluate the pharmacokinetic characteristics of HR1405-01 injection after multiple intravenous administration in healthy humans.

Main study objectives: 1. To quantitatively analyze the total radioactivity in excretion after intravenous infusion of [14C]HR1405-01 injection in healthy male subjects, and obtain the data on human radioactive excretion rate and main excretion pathways; 2. To quantitatively analyze the total radioactivity in whole blood and plasma after intravenous infusion of [14C]HR1405-01 injection in healthy male subjects, obtain the pharmacokinetic parameters of total radioactivity in plasma, and investigate the distribution of total radioactivity in whole blood and plasma; 3. To quantitatively analyze the radioactive metabolite spectrum in human plasma, urine and feces after intravenous infusion of [14C]HR1405-01 injection in healthy male subjects, identify the main metabolites, and determine the main biotransformation pathways and elimination pathways; Secondary study objectives: 4. To quantitatively analyze the concentration of HR1405-01 and its metabolites (if applicable) in plasma, and obtain pharmacokinetic parameters; 5. To observe the safety of single-dose intravenous infusion of [14C]HR1405-01 injection in healthy male subjects.